# Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)

> **NCT03068754** · PHASE2,PHASE3 · TERMINATED · sponsor: **Mallinckrodt** · enrollment: 143 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Acthar
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03068754
- **Lead sponsor:** Mallinckrodt
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-22
- **Primary completion:** 2019-11-25
- **Final completion:** 2019-11-25
- **Target enrollment:** 143 (ACTUAL)
- **Why stopped:** As recommended by the study's independent Data and Safety Monitoring Board (DSMB)
- **Last updated:** 2020-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03068754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03068754, "Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03068754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*